NCT05465252Recruiting
Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression
Effect of Krill Oil Supplementation on Dry Age-Related Macular Degeneration: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
This randomized, double-blind, placebo-controlled study aims to evaluate the effect of krill oil supplementation in patients with dry age-related macular degeneration (AMD). Participants will receive 4 capsules of krill oil or placebo daily for a period of 3 months. Outcomes will be evaluated after 3-month treatment to assess differences between the two study groups.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 9 Jun 2022
- Start date
- 17 Oct 2025
- Primary completion date
- Mar 2026
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Diseases
- Macular degeneration
- NCT number
- NCT05465252
What you commit to
- Study type: Interventional
- Planned participants: 24
- From 17 Oct 2025 to the primary completion date, Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Long-term use of any medications that are associated with retinal or neural toxicities.
- History of supplementation with lutein, zeaxanthin, DHA, or EPA, unless a wash-out period of at least 8 weeks is completed prior to enrollment.
- Received cataract surgery in 3 months.
Other illness
- Any eye with disease that would interfere with the fundus examinations.
- Other conditions: subjects with severe systemic diseases; any condition that causes high risk of drop-out, or low compliance, for instance cognition disorder; have been involved in other trial that interfere with the current visit plan; taking other angiogenesis Inhibitors drugs for treating cancer.
- Other conditions not suitable for the current study.
Other
- Eye with choroidal neovascularization (CNV), geographic atrophy (GA), or high myopia.
- Surgeries that may interfere with AMD evaluation.
- Intraocular pressure more than 26 mmHg.
Who the study is looking for
- Adults diagnosed with dry AMD at an early or intermediate stage, classified according to the Beckman Classification and confirmed by fundus photography: (1) Early AMD: medium drusen (\>63 μm and ≤125 μm) without AMD-related pigmentary abnormalities; (2) Intermediate AMD: large drusen (\>125 μm), with or without AMD-related pigmentary abnormalities.
- Willing to stop supplementation of omega-3 fatty acids, choline, or astaxanthin.
- Willing to sign the informed consent, and willing to attend follow-up visits for at least 3 months.
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai General Hospital, Shanghai Jiao Tong University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.